secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zai Lab Ltd (ZLAB)
CIK:        0001704292
Form:       8-K
Filed at:   2022-09-27T23:59:59+00:00
Accession:  0001628280-22-025522
Event type: m_and_a
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zai Lab licenses TIVDAK from Seagen for China, HK, Macau, Taiwan; $30M upfront plus milestones up to $263M
--------------------------------------------------------------------------------

- Zai Lab pays $30M upfront, up to $78M in dev/reg milestones, and up to $185M in sales milestones.
- Seagen receives tiered royalties from mid-teens to low twenties on net sales in licensed territory.
- Payments shared 50/50 with Genmab under existing Seagen/Genmab co-development agreement.
- TIVDAK is FDA-approved for recurrent/metastatic cervical cancer; Phase 3 trial (innovaTV 301) ongoing.
- Approximately 110,000 new cervical cancer cases annually in China, representing significant unmet need.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1704292/000162828022025522/0001628280-22-025522-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1704292/000162828022025522/zlab-20220923.htm
  HTML page:      https://secwatch.observer/filing/0001628280-22-025522

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer